(E)-1-[2,4-bis(benzyloxy)-6-hydroxyphenyl]-3-[3,4,5-tris(benzyloxy)phenyl]propenone | 333796-77-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: (E)-1-[2,4-bis(benzyloxy)-6-hydroxyphenyl]-3-[3,4,5-tris(benzyloxy)phenyl]propenone
• 英文别名: 2'-hydroxy-4',6',3,4,5-pentabenzyloxy-chalcone；1-(2,4-BIS-BENZYLOXY-6-HYDROXY-PHENYL)-3-(3,4,5-TRIS-BENZYLOXY-PHENYL)-PROPENONE；(E)-1-[2-hydroxy-4,6-bis(phenylmethoxy)phenyl]-3-[3,4,5-tris(phenylmethoxy)phenyl]prop-2-en-1-one
• CAS: 333796-77-3
• 化学式: C₅₀H₄₂O₇
• 分子量: 754.879
• InChiKey: FCLCFIUEFRPZSC-CYYJNZCTSA-N

物化性质

• 熔点：
  148-149 °C(Solv: ethyl ether (60-29-7))
• 沸点：
  919.9±65.0 °C(Predicted)
• 密度：
  1.233±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  11.2
• 重原子数：
  57
• 可旋转键数：
  18
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  83.4
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  (E)-1-[2,4-bis(benzyloxy)-6-hydroxyphenyl]-3-[3,4,5-tris(benzyloxy)phenyl]propenone 在 palladium on activated charcoal N-甲基吗啉 、 4-二甲氨基吡啶 、 sodium tetrahydroborate 、 硼烷四氢呋喃络合物 、 氢气 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 (-)-没食子儿茶素-3-没食子酸酯
  参考文献：
  名称：

  A structure-activity study for the inhibition of metalloproteinase-9 activity and gene expression by analogues of gallocatechin-3-gallate

  摘要：

  Catechins are able to modulate the gelatinolytic activity of matrix metalloproteinase-9 (MMP-9) by reducing its release from macrophages. Gallocatechins decrease MMP-9 secretion by lowering MMP-9 promoter activity and mRNA levels. The effect appears to be dependent on some structural and stereochemical requirements. In this study, the relationship between chemical structure and activity was studied by testing the effect of analogues of (+/-)-gallocatechin-3-gallate (+/-)-GCG, selectively deprived of hydroxyl groups, on MMP-9 activity, transcription, and secretion. Our results indicate that (+/-)-GCG and (+/-)-catechin-3-gallate are characterized by a substitution pattern compatible with direct inhibition of MMP-9 activity. Conversely, when transcription was the target, (+/-)-trans-3-flavanol-3-benzoate, lacking all the hydroxyl groups, was the most effective both in lowering MMP-9 promoter activity and consequently protein secretion, and in inhibiting nuclear-factor-kappa B-driven transcription. Our results suggest that the structural requirements for enzyme inhibition are different from those necessary for targeting gene expression.

  DOI：

  10.1007/s00018-005-5422-7
• 作为产物：
  描述：

  没食子酸甲酯 在 哌啶 、 lithium aluminium tetrahydride 、 potassium carbonate 、 pyridinium chlorochromate 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 (E)-1-[2,4-bis(benzyloxy)-6-hydroxyphenyl]-3-[3,4,5-tris(benzyloxy)phenyl]propenone
  参考文献：
  名称：

  Synthesis of a 3,4,5-Trimethoxybenzoyl Ester Analogue of Epigallocatechin-3-gallate (EGCG):  A Potential Route to the Natural Product Green Tea Catechin, EGCG

  摘要：

  [GRAPHICS]The synthesis of a trimethoxybenzoyl ester (D-ring) analogue of epigallocatechin-3-gallate (EGCG) is described. The versatile synthesis route can be used to synthesize A, B, and D ring analogues of EGCG and involves a key cyclization of the chalcone to the 3-flavene. This synthesis provides a possible route to the polyphenolic green tea natural product EGCG.

  DOI：

  10.1021/ol007000o

文献信息

• Novel flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents
  申请人：——

  公开号：US20040029914A1

  公开（公告）日：2004-02-12

  Novel compounds are useful as chemotherapeutic, chemopreventative, and antiangiogenic agents are provided. The compounds are flavanoids, including flavanones, flavanols, and chalcones. The compounds have the structure of formula (I) 1 wherein R 1 through R 3 and R 5 through R 11 are defined herein, and &agr;, &bgr;, and &ggr; are optional bonds, providing that when &agr; is absent, &bgr; is present, and when &bgr; is absent, &agr; is present. When &agr; is present, preferred R 4 moieties are selected from O, S, NH and CH 2 , and when &agr; is absent, preferred R 4 groups are selected from OH, SH, NH 2 and CH 3 . When &ggr; is present, the preferred R 5 substituent is O, while when &ggr; is absent, the preferred R 5 substituent is OH. Pharmaceutical compositions are provided as well, as are methods of synthesis and use.

  提供了作为化疗、化学预防和抗血管生成药物的有用的新化合物。这些化合物是黄酮类化合物，包括黄酮醇、黄酮醇和香豆素。这些化合物具有公式(I)的结构，其中R1至R3和R5至R11如本文所定义，α、β和γ是可选键，当α不存在时，β存在，当β不存在时，α存在。当α存在时，首选的R4基团选自O、S、NH和CH2，当α不存在时，首选的R4基团选自OH、SH、NH2和CH3。当γ存在时，首选的R5取代基为O，而当γ不存在时，首选的R5取代基为OH。还提供了药物组合物，以及合成和使用方法。
• Enantioselective Synthesis of Flavan-3-ols Using a Mitsunobu Cyclization
  作者：Karsten Krohn、Ishtiaq Ahmed、Markus John

  DOI：10.1055/s-0028-1083361

  日期：——

  The synthesis of four flavan-3-ols with different substitution patterns and electron densities has been achieved in high stereo- and regioselectivity by a one-step Mitsunobu reaction from the corresponding diols, which were prepared by enantioselective Sharpless dihydroxylation of suitable olefins. The six-membered flavan-3-ols were the only cyclization products and the theoretically possible formation of five-membered rings during the Mitsunobu cyclization was not observed. The flavanols are important starting materials for the synthesis of dimers such as the procyanidins or other coupling products such as the flavan part of the potent DNA polymerase β inhibitor myristinin A. The enantioselectivities of both the Sharpless dihydroxylation and the Mitsunobu cyclization steps were monitored by chiral HPLC.

  通过从相应的二醇进行一步Mitsunobu反应，以高立体选择性和区位选择性成功合成了四种具有不同取代模式和电子密度的黄酮-3-醇，这些二醇是通过对合适的烯烃进行手性选择性的Sharpless二羟基化制备的。在Mitsunobu环化过程中，六元环的黄酮-3-醇是唯一的环化产物，理论上可能形成的五元环并未被观察到。这些黄酮醇是合成二聚体（如原花青素）或其他偶联产物（如强效DNA聚合酶β抑制剂myristinin A中的黄酮部分）的重要起始材料。Sharpless二羟基化和Mitsunobu环化步骤的对映选择性通过手性高效液相色谱法进行了监测。
• Analogs of green tea polyphenols as chemotherapeutic and chemopreventive agents
  申请人：——

  公开号：US20040110790A1

  公开（公告）日：2004-06-10

  Novel compounds useful as chemotherapeutic and chemopreventive agents are provided. The compounds are analogs of polyphenol catechins that occur in green tea, such as epigallocatichin-3-gallate (EGCG), and have the structure of formula (I) 1 wherein R 1 through R 11 are defined herein. Preferred R 4 moieties are selected from O, S, NH and CH 2 , and in exemplary compounds, R 4 is O and R 5 is a tri-substituted aroyloxy substituent, such as a 3,4,5-substituted benzoyloxy group. Pharmaceutical compositions are provided as well, as are methods of chemotherapy and chemoprevention.

  提供了作为化疗和化学预防剂有用的新型化合物。这些化合物是绿茶中存在的多酚儿茶素的类似物，如表儿茶素-3-没食子酸酯（EGCG），其结构如式（I）1所示，其中R1至R11在此处定义。首选的R4基团从O、S、NH和CH2中选择，在示例化合物中，R4为O，R5为三取代芳酰氧基取代基，如3,4,5-取代苯甲酰氧基基团。还提供了药物组合物，以及化疗和化学预防的方法。
• METHOD FOR PRODUCING FLAVAN DERIVATIVE
  申请人：Suzuki Keisuke

  公开号：US20090099374A1

  公开（公告）日：2009-04-16

  The present invention provides a method for producing flavan derivatives having various substituent groups with controlling the stereochemistry. The method of the present invention includes the steps of: hydratively condensing a phenol compound expressed by formula (I) and an alcohol compound expressed by formula (II) to from an epoxide compound of formula (III); opening the epoxy ring of the epoxide compound of formula (III) to form an iodine-containing compound of formula (IV); and cyclizing the iodine-containing compound to form the flavan derivative of formula (V).
• US7329687B2
  申请人：——

  公开号：US7329687B2

  公开（公告）日：2008-02-12